# Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

> **NCT01594281** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 107 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy (PDR)

## Interventions

- **DRUG:** Ranibizumab 0.5 mg
- **PROCEDURE:** Panretinal laser photocoagulation

## Key facts

- **NCT ID:** NCT01594281
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-11
- **Primary completion:** 2016-11-30
- **Final completion:** 2017-12-05
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594281, "Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01594281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*